Role of Polymorphisms in the Dectin-1 Gene in Determining the Risk of Candida Colonization and Infection in Critically Ill Patients
The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2011 by Cardiff and Vale University Health Board.
Recruitment status was Not yet recruiting
Information provided by (Responsible Party):
Matt P Wise, Cardiff and Vale University Health Board
First received: November 29, 2011
Last updated: November 30, 2011
Last verified: November 2011
The principal aim of this study is to establish if a polymorphism in a gene important for innate immunity to fungi represents a significant risk factor for the development of Candida colonisation and subsequent invasive candidosis in critically ill patients. Incorporation of a screening programme onto a risk-based algorithm for critical care patients would allow more effective targeting of molecular diagnostic tests, anti-fungal prophylaxis and targeted treatment. Sequential critical care patients will be screened for gene polymorphisms and undergo regular screening for Candida colonization.
||Time Perspective: Prospective
||Role of Polymorphisms in the Dectin-1 Gene in Determining the Risk of Candida Colonization and Infection in Critically Ill Patients
| Estimated Enrollment:
| Study Start Date:
Critical care patients antipated to stay more than 72 hours
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Critical care patients predicted to stay more than 72 hours
- Patients aged > 18 years
- Patients with anticipated or actual critical care unit stay > 72 hours
- Consent or assent (if patient lacks capacity) obtained
- Age < 18 years
- Length of predicted stay on critical care < 72 hours consent or assent not obtained
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01482988
|Critical Care Unit
|University Hospital of Wales, Cardiff, United Kingdom, CF14 4XW |
|Contact: Matt P Wise +44 2920 747747 ext 3608 firstname.lastname@example.org |
|Sub-Investigator: Matt P Wise |
Cardiff and Vale University Health Board
||Matt P Wise
||Cardiff and Vale Local Health Board
No publications provided
||Matt P Wise, Critical Care Consultant, Cardiff and Vale University Health Board
History of Changes
|Other Study ID Numbers:
|Study First Received:
||November 29, 2011
||November 30, 2011
Wales:Cardiff and Vale University Health Board
Keywords provided by Cardiff and Vale University Health Board:
prevalence of the Dectin-1 polymorphism (Tyr238X)
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on November 25, 2014